Digital Platform to Optimize Guideline-Directed Heart Failure Therapy: Results of the AIM-POWER Trial.

Adam D DeVore¹, Maulik Majmudar², Leigh Etters², Jiecheng Xie², Chen Hao², Phillip H Lam³, Adrian F Hernandez¹, Gregg C Fonarow⁴, Akshay S Desai⁵

¹Duke Clinical Research Institute and Department of Medicine, Duke University School of Medicine, Durham, NC (A.D.D., A.F.H.).

²Biofourmis Inc, Nashville, TN (M.M., L.E., J.X., C.H.).

³Georgetown University and Department of Cardiology, MedStar Washington Hospital Center, Washington, DC (P.H.L.).

⁴Division of Cardiology, Department of Medicine, Ronald Reagan-UCLA Medical Center, Los Angeles, CA (G.C.F.).

⁵Cardiovascular Division, Brigham and Women's Hospital, Boston, MA (A.S.D.).

PubMed DOI

Abstract

BACKGROUND: Less than 1 in 3 patients in the United States with heart failure (HF) with reduced ejection fraction are receiving guideline-recommended medical therapy. Remote titration programs outside of structured episodes of care may address this issue and improve the implementation of guideline-recommended care. METHODS: AIM-POWER (Artificial Intelligence Mobile Health Trial of a Digital Platf…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.